Diseases of the native kidneys in dialysis and transplanted patients

  • Norbert Lameire
  • Raymond Vanholder
  • Annemieke Dhondt
  • Wim Van Biesen
Chapter

Abstract

The native kidneys in patients on dialysis or after kidney transplantation tend to be overlooked until problems occur in relation to them. These problems can be variable and do not bear any consistent relationship to the cause of the renal failure, although in some cases, such as polycystic kidney disease, there are specific changes to be seen. This chapter will review several issues that are related to either functional or structural alterations that occur in the native kidneys in patients treated with either hemodialysis, peritoneal dialysis (PD) or kidney transplantation.

Keywords

Renal Cell Carcinoma Dialysis Patient Autosomal Dominant Polycystic Kidney Disease Polycystic Kidney Disease Calcium Oxalate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lameire N, Van Biesen W. The impact of residual renal function on the adequacy of peritoneal dialysis. Pert Dial Int. 1997;17 (Suppl. 2): S. 102–10.Google Scholar
  2. 2.
    Van Biesen W, Lameire NH. Residual renal function in automated peritoneal dialysis. Contrib Nephrol. 1999;129: 229–46.PubMedGoogle Scholar
  3. 3.
    Rottembourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int Suppl. 1993;40:S106–10.Google Scholar
  4. 4.
    Lysaght MJ, Vonesh EF, Gotch F et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans. 1991;37:598–604.PubMedGoogle Scholar
  5. 5.
    Venkataraman V, Nolph KD. Preservation of residual renal function — an important goal (editorial). Perit Dial Int. 2000;20:392–5.PubMedGoogle Scholar
  6. 6.
    Slingeneyer A, De Vecchi A, Faller B et al. Multicentre study on patient referral to dialysis. J Am Soc Nephrol. 1998;9: 226A (abstract).Google Scholar
  7. 7.
    Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000;11:556–64.PubMedGoogle Scholar
  8. 8.
    Misra M, Vonesh E, Churchill DN, Moore HL, Van Stone JC, Nolph KD. Preservation of glomerular filtration rate on dialysis when adjusted for patient dropout. Kidney Int. 2000;57:691–6.PubMedGoogle Scholar
  9. 9.
    McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis. 1997;29:576–83.PubMedGoogle Scholar
  10. 10.
    Mc Kane WS, Tattersall JE, Farrington K. Preservation of residual renal function in high-flux haemodialysis. Nephrol Dial Transplant. 1994;9:1686 (abstract).Google Scholar
  11. 11.
    Hartmann J, Fricke H, Schiffl H. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis. 1997;30: 366–73.PubMedGoogle Scholar
  12. 12.
    Van Stone J. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J. 1995;41: M713–16.Google Scholar
  13. 13.
    Caramelo C, Alcazar R, Gallar P et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant. 1994;9:675–7.PubMedGoogle Scholar
  14. 14.
    Schiffl H. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant. 1995;10:911–12 (letter).PubMedGoogle Scholar
  15. 15.
    Motojima M, Nishijima F, Ikoma M et al. Role of ‘uremic toxin’ in the progressive loss of intact nephrons in chronic renal failure. Kidney Int. 1991;43(Suppl. 40):S.101–10.Google Scholar
  16. 16.
    Van Biesen W, Vanholder R, Van Loo A, Van der Vennet M, Lameire N. Peritoneal dialysis favorably influences early graft function after renal transplantation compared to hemodialysis. Transplantation. 2000;69:508–14.PubMedGoogle Scholar
  17. 17.
    Vanholder R, Heering P, Van Loo A et al. Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. Am J Kidney Dis. 1999;33:934–40.PubMedGoogle Scholar
  18. 18.
    Pascual M, Rabito CA, Tolkoff-Rubin N et al. Contribution of native kidney function to total glomerular filtration rate after combined kidney-pancreas transplantation. Trans-plantation. 1998;65:99–103.Google Scholar
  19. 19.
    Grantham JJ, Chonko AM. The physiologic basis and clinical use of diuretics. In: Brenner BM, Stein JH, editors. Sodium and Water Homeostasis. New York: Churchill Livingstone, 1978:178–211.Google Scholar
  20. 20.
    Fliser D, Schroter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994;46: 482–8.PubMedGoogle Scholar
  21. 21.
    Faller B, Lameire N. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years. Nephrol Dial Transplant. 1994;9:280–6.PubMedGoogle Scholar
  22. 22.
    Bandiani G, Camaiora E, Nicolini MA, Perotta U. Muzolimine in patients on chronic hemodialysis (HD) and continuous ambulatory peritoneal dialysis. Z Kardiol. 1985; 74 (Suppl).Google Scholar
  23. 23.
    van Olden RW, van Meyel JJ, Gerlag PG. Acute and longterm effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol. 1992;12:351–6.PubMedGoogle Scholar
  24. 24.
    Medcalf JF, Harris KP, Walls J. Frusemide increases urine volume, but does not preserve residual renal function in patients on CAPD-results of a six-month randomized, controlled study. Pert Dial Int. 1998;18:S1 (abstract).Google Scholar
  25. 25.
    Medcalf JF, Harris KP, Walls J. What place diuretics in long-term CAPD? (editorial). Nephrol Dial Transplant. 1998;13:2193–4.PubMedGoogle Scholar
  26. 26.
    Guler HP, Eckardt KU, Zapf J, Bauer C, Froesch ER. Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol. 1989;121:101–6.PubMedGoogle Scholar
  27. 27.
    O’Shea MH, Miller SB, Hammerman MR. Effects of IGF-I on renal function in patients with chronic renal failure. Am J Physiol. 1993;264:F917–22.Google Scholar
  28. 28.
    Miller SB, Moulton M, O’Shea M, Hammerman MR. Effects of IGF-I on renal function in end-stage chronic renal failure. Kidney Int. 1994;46:201–7.PubMedGoogle Scholar
  29. 29.
    Ike JO, Fervenza FC, Hoffman AR et al. Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure. Kidney Int. 1997;51:840–9.PubMedGoogle Scholar
  30. 30.
    Vijayan A, Franklin SC, Behrend T, Hammerman MR, Miller SB. Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. Am J Physiol. 1999;276:R929–34.Google Scholar
  31. 31.
    Vijayan A, Behrend T, Miller SB. Clinical use of growth factors in chronic renal failure. Curr Opin Nephrol Hypertens. 2000;9:5–10.PubMedGoogle Scholar
  32. 32.
    Vijayan A, Franklin SC, Delmez JA, Miller SB. Insulin-like growth factor 1 enhances renal function in a patient with chronic renal failure on peritoneal dialysis. Am J Kidney Dis. 2000;35:150–3.PubMedGoogle Scholar
  33. 33.
    Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18.PubMedGoogle Scholar
  34. 34.
    Fishbane S, Maesaka JK, Goreja MA, Kowalski EA. Hypertension in dialysis patients. In: Lameire N, Mehta RL, editors. Complications of Dialysis. New York: Marcel Dekker, 2000:471–84.Google Scholar
  35. 35.
    Campese VM, Chanana A. Hypertension in dialysis patients. In: Henrich WL, editor. Principles and Practice of Dialysis. Baltimore: Williams & Wilkins, 1999:209–34.Google Scholar
  36. 36.
    Sander S, Rettig R, Ehrig B. Role of the native kidney in experimental post-transplantation hypertension. Pflugers Arch. 1996;431:971–6.PubMedGoogle Scholar
  37. 37.
    Doublet J, Belair G. Retroperitoneal laparoscopic nephrectomy is safe and effective in obese patients: a comparative study of 55 procedures. Urology. 2000;56: 63–6.PubMedGoogle Scholar
  38. 38.
    Zazgornik J, Biesenbach G, Janko O et al. Bilateral nephrectomy: the best, but often overlooked, treatment for refractory hypertension in hemodialysis patients. Am J Hypertens. 1998;11:1364–70.PubMedGoogle Scholar
  39. 39.
    Nuutinen M, Lautala P, Remes M, Uhari M. Nephrectomy in severe hypertension. Clin Nephrol. 2000;554:342–6.Google Scholar
  40. 40.
    Curtis JJ. Management of hypertension after transplantation. Kidney Int Suppl. 1993;43:S45–9.Google Scholar
  41. 41.
    van Ypersele de Strihou C. Native kidney in posttransplantation hypertension. Lancet. 1985;2:1243 (letter).Google Scholar
  42. 42.
    Simon J. On subacute inflammation of the kidney. MedicoChir-Trans. 1847;30:141–64.Google Scholar
  43. 43.
    Dunhill MS, Millard PR, Oliver D. Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance hemodialysis. J Clin Pathol. 1977;30:868–77.Google Scholar
  44. 44.
    Ishikawa I. Uremic acquired renal cystic disease. Natural history and complications (editorial). Nephron. 1991;58: 257–67.PubMedGoogle Scholar
  45. 45.
    Grantham JJ. Acquired cystic kidney disease. Kidney Int. 1991;40:143–52.PubMedGoogle Scholar
  46. 46.
    Kenner CH, Evan AP, Blomgren P, Aronoff GR, Luft FC. Effect of protein intake on renal function and structure in partially nephrectomized rats. Kidney Int. 1985;27:739–50.PubMedGoogle Scholar
  47. 47.
    Mangoo-Karim R, Uchic M, Lechene C, Grantham JJ. Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP. Proc Natl Acad Sci USA. 1989; 86:6007–11.PubMedGoogle Scholar
  48. 48.
    Herrera GA. Cerb B-2 amplification in cystic renal disease. Kidney Int. 1991;40:509–13.PubMedGoogle Scholar
  49. 49.
    Gronwald J, Baur AS, Holtgreve-Grez H et al. Chromosomal abnormalities in renal cell neoplasms associated with acquired renal cystic disease. A series studied by comparative genomic hybridization and fluorescence in situ hybridization. J Pathol. 1999;187:308–12.PubMedGoogle Scholar
  50. 50.
    Khurana KK, Truong LD, Verani RR. Image analysis of proliferating cell nuclear antigen expression and immunohistochemical profiles in renal cell carcinoma associated with acquired cystic kidney disease: comparison with classic renal cell carcinoma. Mod Pathol. 1998;11:339–46.PubMedGoogle Scholar
  51. 51.
    Concolino G, Lubrano C, Ombres M, Santonati A, Flammia GP, De Silverio F. Acquired cystic kidney disease: the hormonal hypothesis. Urology. 1993;41:170–5.PubMedGoogle Scholar
  52. 52.
    Cohen EP, Elliott WC Jr. The role of ischemia in acquired cystic kidney disease. Am J Kidney Dis. 1990;15:55–60.PubMedGoogle Scholar
  53. 53.
    Marco-Franco JE, Torres VE, Nixon DE et al. Oxalate, silicon and vanadium in acquired cystic kidney disease. Clin Nephrol. 1991;35:52–8.PubMedGoogle Scholar
  54. 54.
    Narasimhan N, Golper TA, Wolfson M, Rahatzad M, Bennett WM. Clinical characteristics and diagnostic considerations in acquired renal cystic disease. Kidney Int. 1986;30:748–52.PubMedGoogle Scholar
  55. 55.
    Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore). 1990;69:217–26.Google Scholar
  56. 56.
    Miller LR, Soffer O, Nassar VH, Kutner MH. Acquired renal cystic disease in end-stage renal disease: an autopsy study of 155 cases. Am J Nephrol. 1989;9:322–8.PubMedGoogle Scholar
  57. 57.
    Ishikawa I, Saito Y, Shikura N, Kitada H, Shinoda A, Suzuki S. Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis. 1990;16:452–8.PubMedGoogle Scholar
  58. 58.
    Ishikawa I, Saito Y, Nakamura M et al. Fifteen-year followup of acquired renal cystic disease — a gender difference. Nephron. 1997;75:315–20.PubMedGoogle Scholar
  59. 59.
    Schillinger F. Acquired cystic kidney disease in renal insufficiency: a multicentre study. Group of Nephrologists of the East of France. Eur J Med. 1993;2:457–60.PubMedGoogle Scholar
  60. 60.
    Park JH, Kim YO, Park JH et al. Comparison of acquired cystic kidney disease between hemodialysis and continuous ambulatory peritoneal dialysis. Korean J Intern Med. 2000; 15:51–5.PubMedGoogle Scholar
  61. 61.
    Kyushu Pediatric Nephrology Study Group. Acquired cystic kidney disease in children undergoing continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1999;34:242–6.Google Scholar
  62. 62.
    Leichter HE, Dietrich R, Salusky IB et al. Acquired cystic kidney disease in children undergoing long-term dialysis. Pediatr Nephrol. 1988;2:8–11.PubMedGoogle Scholar
  63. 63.
    Pena Porta JM, Pernaute LR. Wunderlich ’s syndrome in a patient on hemodialysis with acquired cystic kidney disease. A report of a new case. Actas Urol Esp. 1999;23:76–8.PubMedGoogle Scholar
  64. 64.
    Segerer S, Meister P. Acquired cystic kidney disease in patients on long-term dialysis: a retrospective study of 125 autopsies. Part 2: Tumors. Pathologe. 1998;19:368–72.PubMedGoogle Scholar
  65. 65.
    Levine E, Slusher SL, Grantham JJ, Wetzel LH. Natural history of acquired renal cystic disease in dialysis patients: a prospective longitudinal CT study. Am J Roentgenol. 1991;156:501–6.Google Scholar
  66. 66.
    Marple JT, MacDougall M, Chonko AM. Renal cancer complicating acquired cystic kidney disease (See comments). J Am Soc Nephrol. 1994;4:1951–6.PubMedGoogle Scholar
  67. 67.
    Truong LD, Krishnan B, Cao JT, Barrios R, Suki WN. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis. 1995;26:1–12.PubMedGoogle Scholar
  68. 68.
    Levine E, Hartman DS, Meilstrup JW, Van Slyke MA, Edgar KA, Barth JC. Current concepts and controversies in imaging of renal cystic diseases. Urol Clin N Am. 1997; 24:523–43.Google Scholar
  69. 69.
    Takebayashi S, Hidai H, Chiba T, Takagi H, Koike S, Matsubara S. Using helical CT to evaluate renal cell carcinoma in patients undergoing hemodialysis: value of early enhanced images. Am J Roentgenol. 1999;172:429–33.Google Scholar
  70. 70.
    Tantravahi J, Steinman TI. Acquired cystic kidney disease. Semin Dial. 2000;13:330–4.PubMedGoogle Scholar
  71. 71.
    Heinz-Peer G, Maier A, Eibenberger K et al. Role of magnetic resonance imaging in renal transplant recipients with acquired cystic kidney disease. Urology. 1998;51:534–8.PubMedGoogle Scholar
  72. 72.
    Querfeld U, Schneble F, Wradzidlo W, Waldherr R, Troger J, Scharer K. Acquired cystic kidney disease before and after renal transplantation. J Pediatr. 1992;121:61–4.PubMedGoogle Scholar
  73. 73.
    Sarasin FP, Wong JB, Levey AS, Meyer KB. Screening for acquired cystic kidney disease: a decision analytic perspective. Kidney Int. 1995;48:207–19.PubMedGoogle Scholar
  74. 74.
    Allan PL. Ultrasonography of the native kidney in dialysis and transplant patients. J Clin Ultrasound. 1992;20: 557–67.PubMedGoogle Scholar
  75. 75.
    Lien YH, Kam I, Shanley PF, Schroter GP. Metastatic renal cell carcinoma associated with acquired cystic kidney disease 15 years after successful renal transplantation. Am J Kidney Dis. 1991;18:711–15.PubMedGoogle Scholar
  76. 76.
    Lien YH, Hunt KR, Siskind MS, Zukoski C. Association of cyclosporin A with acquired cystic kidney disease of the native kidneys in renal transplant recipients. Kidney Int. 1993;44:613–16.PubMedGoogle Scholar
  77. 77.
    Renoult E, Kessler M. Carcinoma of the native kidney in patients with renal transplantation. A French multicenter study. J Radiol. 1994;75:49–52.PubMedGoogle Scholar
  78. 78.
    Doublet JD, Peraldi MN, Gattegno B, Thibault P, Sraer JD. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol. 1997;158:42–4.PubMedGoogle Scholar
  79. 79.
    Riehl J, Schmitt H, Fritz A, Fuzesi L, Sieberth HG. Renal oncocytoma of the native kidney after renal transplantation. Am J Nephrol. 1998;18:160–3.PubMedGoogle Scholar
  80. 80.
    Gulanikar AC, Daily PP, Kilambi NK, Hamrick-Turner JE, Butkus DE. Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation. 1998;66:1669–72.PubMedGoogle Scholar
  81. 81.
    Chagnac A, Zevin D, Weinstein T, Gafter U, Korzets A, Levi J. Erythrocytosis associated with renal artery thrombosis in a patient with polycystic kidney disease on hemodialysis. Acta Haematol. 1990;84:40–2.PubMedGoogle Scholar
  82. 82.
    Fernandez A, Hortal L, Rodriguez JC, Vega N, Plaza C, Palop L. Anemia in dialysis: its relation to acquired cystic kidney disease and serum levels of erythropoietin. Am J Nephrol. 1991;11:12–15.PubMedGoogle Scholar
  83. 83.
    Schillinger F. Erythropoiesis in dialysis patients with acquired cystic kidney disease. Collaborative Group of Nephrologists of the East of France. Nephron. 1994;66:119–20 (letter).Google Scholar
  84. 84.
    Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis. 1994; 24:1–11.PubMedGoogle Scholar
  85. 85.
    Martino R, Oliver A, Ballarin JM, Remacha AF. Postrenal transplant erythrocytosis: further evidence implicating erythropoietin production by the native kidneys. Ann Hematol. 1994;68:201–3.PubMedGoogle Scholar
  86. 86.
    Norby SM, Torres VE. Complications of autosomal dominant polycystic kidney disease in hemodialysis patients. Semin Dial. 2000;13:30–5.PubMedGoogle Scholar
  87. 87.
    Pirson Y, Christophe JL, Goffin E. Outcome of renal replacement therapy in adult polycystic kidney disease. Nephrol Dial Transplant. 1996;11(Suppl. 6):24–8.PubMedGoogle Scholar
  88. 88.
    Sweet R, Keane WF. Perinephric abcess in patients with polycystic kidney disease undergoing chronic hemodialysis. Nephron. 1979;23:237–40.PubMedGoogle Scholar
  89. 89.
    Schwab SJ, Bander SJ, Klahr S. Renal infections in autosomal dominant polycystic kidney disease. Am J Med. 2000;82:714–18.Google Scholar
  90. 90.
    Elzinga LW, Bennett WM. Miscellaneous renal and systemic complications of autosomal dominant polycystic kidney disease including infection. In: Watson ML, Torres VE, editors. Polycystic Kidney Disease. New York: Oxford University Press, 1996:530–47.Google Scholar
  91. 91.
    Culleton B, Parfrey PS. Management of end-stage renal failure and problems of transplantation in autosomal dominant polycystic kidney disease. In: Watson ML, Torres VE, editors. Polycystic Kidney Disease. New York: Oxford University Press, 1996:450–61.Google Scholar
  92. 92.
    Betan PR Jr, Price DC, McClure RD. Localization of abscess in adult polycystic kidney disease by indium-111 leukocyte scan. Urology. 1988;32:169–71.Google Scholar
  93. 93.
    Levine E, Grantham JJ. The role of computed tomography in the evaluation of adult polycystic kidney disease. Am J Kidney Dis. 1981;1:99–105.PubMedGoogle Scholar
  94. 94.
    Cuppage FE, Huseman RA, Chapman A, Grantham JJ. Ultrastructure and function of cysts from human adult polycystic kidneys. Kidney Int. 1980;17:372–81.PubMedGoogle Scholar
  95. 95.
    Grantham JJ, Geiser JL, Evan AP. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int. 1987;31:1145–52.PubMedGoogle Scholar
  96. 96.
    Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM. TMP-SMX in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int. 1987;32:884.PubMedGoogle Scholar
  97. 97.
    Schwab SJ, Himthorn D, Diederich D, Cuppage F, Grantham JJ. pH-dependent accumulation of clindamycin in a polycystic kidney. Am J Kidney Dis. 1983;3:63–6.PubMedGoogle Scholar
  98. 98.
    Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM. Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother. 1988;32:844–7.PubMedGoogle Scholar
  99. 99.
    Laing RB, Smith FW, Douglas JG. Salmonella enteritidis urinary infection associated with polycystic renal disease. J Infect. 1993;27:71–3.PubMedGoogle Scholar
  100. 100.
    Rossi SJ, Healy DP, Savani DV, Deepe G. High-dose ciprofloxacin in the treatment of a renal cyst infection. Ann Pharmacother. 1993;27:38–9.PubMedGoogle Scholar
  101. 101.
    Aronoff GR, Berns JS, Brier ME et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 4th edn. Philadelphia: American College of Physicians-American Society of Internal Medicine, 1999.Google Scholar
  102. 102.
    Chapman AB, Thickman D, Gabow PA. Percutaneous cyst puncture in the treatment of cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1990; 16:252–5.PubMedGoogle Scholar
  103. 103.
    Christophe JL, van Ypersele de Strihou C, Pirson Y. Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The U.C.L. Collaborative Group. Nephrol Dial Transplant. 1996;11:1271–6.PubMedGoogle Scholar
  104. 104.
    Gabow PA, Ikle DW, Holmes JH. Polycystic kidney disease: prospective analysis of nonazotemic patients and family members. Ann Intern Med. 1984;101:238–47.PubMedGoogle Scholar
  105. 105.
    Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1992;20:140–3.PubMedGoogle Scholar
  106. 106.
    Zwettler U, Zeier M, Andrassy K, Geberth S, Rambausek M. Treatment of gross hematuria in autosomal dominant polycystic kidney disease with aprotinin and desmopressin acetate. Nephron. 1992;60:374 (letter).Google Scholar
  107. 107.
    Milutinovic J, Fialkow PJ, Agodoa LY, Phillips LA, Rudd TG, Bryant JI. Autosomal dominant polycystic kidney disease: symptoms and clinical findings. Q J Med. 1984;53: 511–22.PubMedGoogle Scholar
  108. 108.
    Haddy SM, Shely WW, Rice N. Intravascular thrombosis after exsanguination in a patient treated with epsilonaminocaproic acid. J Cardiothorac Vasc Anesth. 1996;10: 510–12.PubMedGoogle Scholar
  109. 109.
    Wymenga LF, van der Boon WJ. Obstruction of the renal pelvis due to an insoluble blood clot after epsilonaminocaproic acid therapy: resolution with intraureteral streptokinase instillations. J Urol. 1998;159:490–2.PubMedGoogle Scholar
  110. 110.
    Perazella MA, Biswas P. Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis. 1999;33:782–5.PubMedGoogle Scholar
  111. 111.
    Delaney VB, Adler S, Bruns FJ, Licinia M, Segel DP, Fraley DS. Autosomal dominant polycystic kidney disease: presentation, complications, and prognosis. Am J Kidney Dis. 1985;5:104–11.PubMedGoogle Scholar
  112. 112.
    Harley JD, Shen FH, Carter SJ. Transcatheter infarction of a polycystic kidney for control of recurrent hemorrhage. Am J Roentgenol. 1980;134:818–20.Google Scholar
  113. 113.
    Sholder AJ, Grayhack JT. Management of pain and hemorrhage. In: Grantham JJ, Gardner KD, editors. Problems in Diagnosis and Management of Polycystic Kidney Disease. Kansas City: Intercollegiate Press, 1985: 111–20.Google Scholar
  114. 114.
    Keith DS, Torres VE, King BF, Zincki H, Farrow GM. Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;4:1661–9.PubMedGoogle Scholar
  115. 115.
    Gregoire JR, Torres VE, Holley KE, Farrow GM. Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1987;9:27–38.PubMedGoogle Scholar
  116. 116.
    Harris SA, Brown EA. Patients surviving more than 10 years on haemodialysis. The natural history of the complications of treatment. Nephrol Dial Transplant. 1998;13:1226–33.PubMedGoogle Scholar
  117. 117.
    D ’Agata EM, Mount DB, Thayer V, Schaffner W. Hospitalacquired infections among chronic hemodialysis patients. Am J Kidney Dis. 2000;35:1083–8.PubMedGoogle Scholar
  118. 118.
    Eisinger RP, Asghar F, Kolasa C, Weinstein MP. Does pyuria indicate infection in asymptomatic dialysis patients? Clin Nephrol. 1997;47:50–1.PubMedGoogle Scholar
  119. 119.
    Chaudhry A, Stone WJ, Breyer JA. Occurrence of pyuria and bacteriuria in asymptomatic hemodialysis patients. Am J Kidney Dis. 1993;21:180–3.PubMedGoogle Scholar
  120. 120.
    Higgins RM. Infections in a renal unit. Q J Med. 1989;70: 41–51.PubMedGoogle Scholar
  121. 121.
    Lees JA, Falk RM, Stone WJ, McDougal WS. Pyocystis, pyonephrosis and perinephric abscess in end stage renal disease. J Urol. 1985;134:716–19.PubMedGoogle Scholar
  122. 122.
    Saitoh H, Nakamura K, Hida M, Satoh T. Urinary tract infection in oliguric patients with chronic renal failure. J Urol. 1985;133:990–3.PubMedGoogle Scholar
  123. 123.
    Remer EE, Peacock WFIV. Pyocystis: two case reports of patients in renal failure. J Emerg Med. 2000;19:131–3.PubMedGoogle Scholar
  124. 124.
    Cheng PT, Reid A, Millard J, Pritzker KP, Khanna R, Oreopoulos DG. Ultrastructural studies of renal stones from patients on continuous ambulatory peritoneal dialysis. Scan Electron Microsc. 1983;4:1939–46.Google Scholar
  125. 125.
    Bommer J, Ritz E, Tschope W, Waldherr R, Gebhardt M. Urinary matrix calculi consisting of microfibrillar protein in patients on maintenance hemodialysis. Kidney Int. 1979;16: 722–8.PubMedGoogle Scholar
  126. 126.
    Daudon M, Lacour B, Jungers P et al. Urolithiasis in patients with end stage renal failure. J Urol. 1992;147:977–80.PubMedGoogle Scholar
  127. 127.
    Oren A, Husdan H, Cheng PT et al. Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 1984;25:534–8.PubMedGoogle Scholar
  128. 128.
    Rieu P, Hertig A, Duvic C, Chretien Y, Jungers P, Grünfeld JP. Struvite encrusted pyelitis of native kidneys. J Am Soc Nephrol. 1999;10:149A (abstract).Google Scholar
  129. 128.
    Rieu P, Hertig A, Duvic C, Chretien Y, Jungers P, Grünfeld JP. Struvite encrusted pyelitis of native kidneys. J Am Soc Nephrol. 1999;10:149A (abstract).Google Scholar
  130. 130.
    Ozasa H, Suzuki T, Takahashi K, Ota K. Protein components of amyloid-like kidney stones of chronic hemodialysis patients. Nephron. 1989;53:257–60.PubMedGoogle Scholar
  131. 131.
    Watanabe K, Nakamura R, Kano S, Ohtake T, Hosoda Y, Saruta T. Amyloid urinary-tract calculi in patients on chronic dialysis. Nephron. 1989;52:334–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2004

Authors and Affiliations

  • Norbert Lameire
  • Raymond Vanholder
  • Annemieke Dhondt
  • Wim Van Biesen

There are no affiliations available

Personalised recommendations